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Abstract
IMPORTANCE Simple measures of hypertension treatment, such as achievement of blood pressure
(BP) targets, ignore the intensity of treatment once the BP target is met. High-intensity treatment
involves increased treatment burden and can be associated with potential adverse effects in older
adults. A method was previously developed to identify older patients receiving intense hypertension
treatment by low BP and number of BP medications using national Veterans Health Administration
and Medicare Part D administrative pharmacy data to evaluate which BP medications a patient is
likely taking on any given day.
OBJECTIVE To further develop and validate a method to more precisely quantify dose intensity of
hypertension treatment using only health system administrative pharmacy fill data.
DESIGN, SETTING, AND PARTICIPANTS Observational, cross-sectional study of 319 randomly
selected older veterans in the national Veterans Health Administration health care system who were
taking multiple BP-lowering medications and had a total of 3625 ambulatory care visits from July 1,
2011, to June 30, 2013. Measure development and medical record review occurred January 1, 2017,
through November 30, 2018, and data analysis was conducted from December 1, 2019, to August
31, 2020.
MAIN OUTCOMES AND MEASURES For each BP-lowering medication, a moderate hypertension
daily dose (HDD) was defined as half the maximum dose above which no further clinical benefit has
been demonstrated by that medication in hypertension trials. Patients’ total HDD was calculated
using pharmacy data (pharmacy HDDs), accounting for substantial delays in refills (>30 days) when a
patient’s pill supply was stretched (eg, cutting existing pills in half). As an external comparison, the
pharmacy HDDs were correlated with doses manually extracted from clinicians’ visit notes (clinically
noted HDDs). How well the pharmacy HDDs correlated with clinically noted HDDs was calculated
(using C statistics). To facilitate interpretation, HDDs were described in association with the number
of medications.
RESULTS A total of 316 patients (99.1%) were male; the mean (SD) age was 75.6 (7.2) years.
Pharmacy HDDs were highly correlated (r = 0.92) with clinically noted HDDs, with a mean (SD) of 2.7
(1.8) for pharmacy HDDs and 2.8 (1.8) for clinically noted HDDs. Pharmacy HDDs correlated with
high-intensity, clinically noted HDDs ranging from a C statistic of 92.8% (95% CI, 92.0%-93.7%) for
2 or more clinically noted HDDs to 88.1% (95% CI, 85.5%-90.6%) for 6 or more clinically
noted HDDs.
CONCLUSIONS AND RELEVANCE This study suggests that health system pharmacy data may be
used to accurately quantify hypertension regimen dose intensity. Together with clinic-measured BP,
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Abstract (continued)
this tool can be used in future health system–based research or quality improvement efforts to fine-
tune, manage, and optimize hypertension treatment in older adults.
JAMA Network Open. 2021;4(1):e2034059. doi:10.1001/jamanetworkopen.2020.34059
Introduction
The current approach to assess the quality of hypertension treatment in health care systems remains
limited to dichotomous measures of blood pressure (BP) (ie, percentage of patients with a BP
controlled below target) regardless of the recommended number and doses of medications.
However, there is increasing evidence that intensifying treatment is associated with clinical benefit
for older adults, either by increasing doses and starting new agents1-5 or by prescribing specific
medication classes for their noncardiovascular benefits (eg, angiotensin-converting enzyme
inhibitors for kidney protection).6 As our health care system responds by developing new guidelines
and measures to promote lower BP goals, we need more refined tools to guide safe approaches to
treatment intensification for older adults.
National public health efforts track hypertension treatment by surveying whether patients are
receiving pharmacologic treatment or not,7,8 while hypertension trials demonstrate effectiveness as
the increment in the number of BP medications.2,5,9 However, neither of these approaches captures
dose intensity, a component of medical treatment that is of particular interest to older adults, who
are prone to dose-related adverse effects as a result of frailty, total medication burden, or comorbid
conditions and who often prefer lower medication intensity.10,11
Being able to estimate a standardized hypertension daily dose (HDD) across medications of
differing potency may enable health care systems to develop approaches to intensifying treatment
in addition to monitoring the BP level achieved. Moreover, a decrease in dose intensity may be an
older patient’s only indicator of improved adherence to nonpharmacologic hypertension treatment
(eg, diet)12 because patients might be able to reduce their medication doses while maintaining
appropriate BP control. Last, such a tool would also more precisely identify which older patients
might be appropriate candidates for deintensification of treatment.
An algorithm was previously developed and validated to assess treatment intensity measured
as the number of medications based only on reliable administrative pharmacy fill data within a
complex electronic medical record and health care data system.13 The goal of the present study was
to (1) extend the method to capture daily dose, defined as moderate HDD, for each BP-lowering
medication; (2) validate that the total HDDs calculated from pharmacy data across multiple
medications reflect the intensity of patients’ overall antihypertension medication regimens; and (3)
describe the association between the new HDD measure and the traditional medication count.
Methods
Population
A previous study described the sampling strategy for this cohort of moderately to intensely treated
veterans13 selected from a national sample of older (65 years) Veterans Health Administration
patients with hypertension (International Classification of Diseases, Ninth Revision code 401.x),
receiving primary care over 2 years (from July 1, 2011, to June 30, 2013), taking 3 or more BP
medications, and having a systolic BP less than 120 mm Hg for 2 or more consecutive visits. The
strategy ensured that we had an adequate number of visits while receiving multiple BP medications
to validate. Of 66 412 older veterans meeting the inclusion criteria, we randomly selected 319
patients with 3625 primary care visits.13 This study was approved by the Veterans Affairs (VA)
institutional review board with a waiver of informed consent granted to obtain an unbiased,
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retrospective sample among eligible patients (many who were not expected to be alive at the time
the study was conducted). We followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline.
Assignment of Standardized Moderate Doses
We (L.M. and W.C.C.) reviewed all antihypertensive medications on the VA national formulary,14 in
the American College of Cardiology/American Heart Association hypertension guidelines,15 and in the
Anatomic Therapeutic Class/Defined Daily Dose (ATC/DDD) database.16 For each medication, we
identified the maximum dose demonstrated in controlled hypertension trials above which no further
clinical benefit was expected as supported by evidence synthesis in the seventh and eighth reports
of the Joint National Committee17,18 and the American College of Cardiology/American Heart
Association hypertension guidelines15 and supplemented by specific literature reviews.19-28 These
documents also identified minimum starting doses for older patients (Table 1).15,17-22,24,26-28 Last, we
defined a standardized unit of measurement, the HDD, as half the maximum beneficial dose because
most of the antihypertensive effectiveness is achieved at moderate doses.29 For example, lisinopril’s
maximum effective dose is 40 mg, so we chose 20 mg as 1 standardized HDD unit. Thus, a patient
with 2 HDDs could be taking a maximum dose of 1 medication or half the maximum beneficial dose of
2 different BP medications.
We assigned HDDs for (1) angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers, (2) calcium channel blockers, (3) thiazides or thiazide-like diuretics, (4) potassium-sparing
diuretics, (5) β-blockers, (6) centrally acting α-agonists, (7) vasodilators, and (8) direct renin blockers
(Table 1). Loop diuretics, nitrates, and α-blockers also decrease BP, so we assigned HDDs to these
agents. However, these classes were excluded from analysis because they were frequently
prescribed on an as-needed basis, with dose changes between visits for nonhypertension care, or
were rarely documented as part of hypertension treatment.
The HDDs that we assigned were updated from the ATC/DDDs to reflect modern hypertension
trial evidence, as trials have used new classes and newer doses of medications not historically used
for hypertension control. Whereas the explicit purpose of the ATC is to establish a stable international
standardized dose unit,30 the clinical evidence led us to assign HDDs that differed from the DDDs in
32 of 55 medications (58.2%) that we reviewed. Hypertension daily doses were lower than the DDDs
for several β-blockers (eg, metoprolol tartrate: HDD, 100 mg; DDD, 150 mg) and diuretics (eg,
spironolactone: HDD, 50 mg; DDD, 75 mg), whereas the HDDs were greater than the DDDs for
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (eg, lisinopril: HDD, 20
mg; DDD, 10 mg) (eTable 1 in the Supplement).
Data
We obtained medication data from the national VA Clinical Data Warehouse, including Veterans
Health Administration pharmacy records and Medicare Part D claims during the study period. From
the claims, we extracted medication name, doses, date of fill, and days’ supply of pills dispensed.
Data analysis occurred at the level of the visit. The total HDD was calculated on the date of every
eligible visit. Eligible visits included outpatient primary care visits (with physicians, nurses, advanced
practice clinicians, and pharmacists) in family, general, and geriatric medicine as well as outpatient
nephrology, endocrinology, cardiology, and neurology owing to their expertise in managing BP
medications.
Base Algorithm to Evaluate Medication Exposure During Each Visit
A previous study has described how pharmacy fills can be used to evaluate which BP medications a
veteran is receiving on any given day.13 In brief, our approach sorts all pharmacy fills as a longitudinal
series of events, classifying BP medications into classes. Second, using the pattern of fill dates and
pill supply in association with the visit day, the algorithm evaluates whether or not a patient is taking
a medication on a long-term basis. Medications need to be filled within 186 days both before and
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Table 1. Blood Pressure Medications and Doses













10 20 40 2017 ACC/AHA15 and JNC 717
Captopril 25 50 100 JNC 717
Enalapril maleate 5 20 40 2017 ACC/AHA15 and JNC 717
Fosinopril sodium 10 20 40 2017 ACC/AHA15 and JNC 717




7.5 15 30 2017 ACC/AHA15 and JNC 717
Perindopril erbumine 4 8 16 2017 ACC/AHA15
Quinapril hydrochloride 20 40 80 2017 ACC/AHA15 and JNC 717
Ramipril 2.5 10 20 2017 ACC/AHA15 and JNC 717
Trandolapril 1 2 4 2017 ACC/AHA15 and JNC 717
Azilsartan medoxemil 20 40 80 2017 ACC/AHA15
Candesartan cilexetil 8 16 32 2017 ACC/AHA15 and JNC 717
Eprosartan mesylate 400 600 800 JNC 717 and JNC 818
Irbesartan 75 150 300 2017 ACC/AHA15
Losartan potassium 25 50 100 JNC 717
Olmesartan medoxomil 5 20 40 2017 ACC/AHA15 and JNC 717
Telmisartan 20 40 80 2017 ACC/AHA15 and JNC 717




Amlodipine besylate 2.5 5 10 2017 ACC/AHA15 and JNC 717
Diltiazem hydrochloride 120 240 420 2017 ACC/AHA15 and JNC 717
Felodipine 2.5 5 10 2017 ACC/AHA15
Isradipine 2.5 5 10 JNC 717
Nicardipine
hydrochloride
60 90 120 2017 ACC/AHA15 and JNC 717
Nifedipine 30 60 90a 2017 ACC/AHA15
Nisoldipine 8.5 17 34 2017 ACC/AHA15
Verapamil
hydrochloride
120 240 480 JNC 717
Thiazide and thiazide-like
diuretics (3)
Chlorthalidone 12.5 12.5 25 2017 ACC/AHA,15 JNC 7,17
and JNC 818
Hydrochlorothiazide 12.5 25 50 JNC 717 and JNC 818
Indapamide 1.25 2.5 5 Chaffman et al20
and Caruso et al19
Metolazone 2.5 5 5a 2017 ACC/AHA15
Polythiazide 2 2 4 JNC 717
Bendroflumethiazide 2.5 5 10 JNC 818
Potassium-sparing
diuretics (4)
Amiloride hydrochloride 2.5 5 10 2017 ACC/AHA15 and JNC 717
Eplerenone 25 50 100 2017 ACC/AHA15 and JNC 717
Spironolactone 25 50 100 2017 ACC/AHA15
Triamterene 25 50 100 2017 ACC/AHA15 and JNC 717
(continued)
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after a visit to be considered as a continuous medication. For discontinued medications (filled prior
to but not after the visit), the visit was required to fall within 80% of days’ supply after starting a new
medication or within 90% of days’ supply of dispensing an old medication.13 This algorithm
evaluated the number of medications.
Determining Total Standardized Doses of BP Medications
Next, we assigned standardized dose units to each medication at each visit, modifying a method to
capture refill compliance.31 First, for each medication, we captured doses dispensed at the last fill
Table 1. Blood Pressure Medications and Doses (continued)











Acebutolol hydrochloride 200 400 800 2017 ACC/AHA15 and JNC 717
Atenolol 25 50 100 2017 ACC/AHA,15 JNC 7,17
and JNC 818
Bisoprolol fumarate 2.5 5 10 2017 ACC/AHA15 and JNC 717
Carvedilol phosphate 12.5 25 50 2017 ACC/AHA15 and JNC 717
Labetalol hydrochloride 200 400 800 2017 ACC/AHA15 and JNC 717
Metoprolol tartrate or
succinate
50 100 200 2017 ACC/AHA,15 JNC 7,17
and JNC 818
Nadolol 40 80 120 2017 ACC/AHA15 and JNC 717
Nebivolol hydrochloride 5 20 40 2017 ACC/AHA15
Penbutolol sulfate 10 20 40 2017 ACC/AHA15 and JNC 717
Pindolol 10 30 60 2017 ACC/AHA15
Propranolol hydrochloride 40 80 160 2017 ACC/AHA15





0.2; 0.1 0.4; 0.2 0.8; 0.3 2017 ACC/AHA15 and JNC 717
Guanfacine hydrochloride 0.5 1 2 2017 ACC/AHA15 and JNC 717
Methyldopa 250 500 1000 2017 ACC/AHA15 and JNC 717
Reserpine 0.05 0.125 0.25 JNC 717
Vasodilators (7)
Hydralazine hydrochloride 50 100 200 JNC 717
Minoxidil 5 20 80 2017 ACC/AHA15 and JNC 717
Direct renin blocker (8)
Aliskiren hemifumarate 75 150 300 2017 ACC/AHA15
α-Blockers (9)b
Doxazosin mesylateb 4 8 16 Kirby22
Prazosin hydrochlorideb 2 10 20 Levy24
Silodosinb 4 4 8 Yoshida et al28
Terazosin hydrochlorideb 2 10 20 2017 ACC/AHA15 and JNC 717
Loop diuretics (10)b
Bumetanideb 0.5 1 2 JNC 717
Furosemideb 20 40 80 Musini et al26




30; 4.8 120; 9.6 480; 19.2 Duchier et al21
Isosorbide mononitrateb 30 60 240 Duchier et al21
Abbreviations: ACC/AHA, American College of
Cardiology/American Heart Association; HDD,
hypertension daily dose; JNC, Joint National
Committee.
a The original maximal beneficial dose reflects the
revised guidelines for hypertension by the ACC/AHA,
which were updated only for these 2 medications
in 2018.15
b Minimum and maximum beneficial doses and
citations are provided for these blood pressure–
lowering medications that can be used in the
treatment of hypertension as second-line agents;
however, these medications were not included in the
medical record validation analysis owing to frequent
as-needed dosing, frequent changes in dosing
between visits and refills, and inconsistent
documentation in the clinical notes as being part of
the treatment plan for essential hypertension.
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prior to the visit (“prefill”). Then, we evaluated the time between the prefill and the refill. For
example, if 90 pills of lisinopril, 40 mg, were dispensed for a 90-day supply (3600 mg in total) and
the refill happened within 90 days, then we assigned 3600 mg/90 days or 40 mg/d to lisinopril.
Thus, 40 mg/d, or 2 HDD units, for lisinopril would be added to the total HDDs. If the time elapsed
between the prefill and the refill was greater than the days’ supply and the visit occurred after the
expected refill date, we presumed that the daily dose was stretched uniformly across the days. For
example, if 120 days elapsed, the daily dose was considered to be 30 mg (3600 mg/120 days)
instead of 40 mg, or 1.5 standardized HDD units. For discontinued medications, we assumed the daily
dose to be the last dispensed daily dose. The methods, including SAS codes, are described in further
detail in eTable 2 in the Supplement. The total HDD was calculated for each medication for every visit.
Clinical Note Review
To validate HDD estimates from pharmacy data only (or pharmacy HDDs), 4 trained abstractors (L.G.
and A.L.) reviewed free-text clinical notes in the medical record (including narrative, medication list,
problem list, assessment, and plan) to obtain all documented BP medications and doses during the
study period. To evaluate the BP medications taken on the day of each eligible visit (ie, prior to any
recommended changes), reviewers read all visit notes, including interval notes (ie, telephone notes,
emergency department visits, hospital discharge summaries, and non-VA facility visits). Any
medication documented as being present but of unknown dose was presumed to be 1 HDD, which
occurred in 0.2% of medications abstracted (22 of 9488). We calculated HDDs by the record
(clinically noted HDDs) as a simple sum of HDDs across all medications in each visit note. In contrast
to pharmacy HDDs, we made no adjustments to the clinically noted HDDs for late refills.
Statistical Analysis
Statistical analysis was performed from December 1, 2019, to August 31, 2020. The correlation
coefficient between pharmacy HDDs and clinically noted HDDs was the primary basis for assessing
concordance, accounting for the clustering of visits for each patient. With the clinically noted HDDs
as the external standard, we tested the ability for pharmacy HDDs to correlate with clinically noted
HDDs across varying criteria for a more intense regimen (2, 3, 4, 5, and 6 HDDs) using
sensitivity, specificity, and overall C statistic.
Finally, to help us understand the clinical meaning of the pharmacy HDDs, we described the
distribution (mean, range, SD, and mode) of the number of BP medications corresponding to
pharmacy HDD categories. We highlighted the visits in which using simple counts of medications
might potentially overestimate intensity if used alone (a number greater than HDDs by 0.5 units) and
in which the number might potentially underestimate intensity if used alone (a number less than
HDDs by 2 units). Data were analyzed using SAS statistical software, version 9.4 (SAS Institute Inc)
and Stata 15 (StataCorp).
Results
The sample of 319 patients with 3625 visits (mean [SD], 11.4 [8.3] visits per patient) was 99.1% male
(n = 316) with a mean (SD) age of 75.6 (7.2) years. The mean (SD) systolic BP was 121.9 (16.4) mm Hg
(range, 79.8-201.5 mm Hg) (Table 2). The mean (SD) number of BP medications according to the
medical record was 2.6 (1.0). The mean (SD) clinically noted HDD was 2.8 (1.8) (range, 0-11), similar
to the mean (SD) pharmacy HDD (2.7 [1.8]; range, 0-11) (ie, between 2 and 3 medications at a
moderate dose). Among the first-line medications, the mean (SD) class-specific HDD unit ranged
from 0.9 (0.5) for thiazides to 1.3 (0.6) for calcium channel blockers. The correlation between
pharmacy HDDs and clinically noted HDDs at the level of the visit (3625 visits, adjusted for 319
patient clusters) was 0.92 (Figure). After the addition of the Medicare Part D data, the correlation
coefficient did not change. The pharmacy HDDs were lower than clinically noted HDDs in 1209 visits
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(33.4%), higher than clinically noted HDDs in 553 visits (15.3%), and identical to clinically noted HDDs
in approximately half the visits (1863 [51.4%]).
The ability of the pharmacy HDD to detect a clinically noted HDD regimen of 2 or more, 3 or
more, 4 or more, 5 or more, or 6 or more HDDs was the most sensitive (91.5%) for 2 or more HDDs
and the most specific (99.0%) for 6 or more HDDs (Table 3). Considering the overall ability of
pharmacy HDDs to correlate with clinically noted HDDs, C statistics ranged from 92.8% (95% CI,
92.0%-93.7%) for 2 or more clinically noted HDDs to 88.1% (95% CI, 85.5%-90.6%) for 6 or more
clinically noted HDDs.
The distribution of the number of pharmacy fill BP medications (Table 4) demonstrated that, at
most visits, veterans were taking 2 medications (1315 visits [36.3%]) or 3 medications (1328 visits
[36.6%]). Use of multiple medications was common even at lower HDDs. Nearly one-fourth (76 of
308 [24.7%]) of visits with 0.5 or fewer HDDs were associated with 2 or 3 medications, and 278 of
Table 2. Sample Characteristicsa,b
Variable Mean (SD) [range]
SBP per visit, mm Hg 121.9 (16.4) [79.8-201.5]
Taking ≥3 medications, No. (%) 1890 (52.1)
HDD 2.8 (1.8) [0-11]c
On ≥3 HDDs, No. (%) 1585 (43.7)
Medication class (any during study period), No. (%)
β-Blocker 2912 (80.3)
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 2856 (78.8)
Calcium channel blocker 1518 (41.9)
Thiazide or thiazide-like diuretic 1195 (33.0)
Potassium-sparing diuretic 583 (16.1)
Other vasodilator 140 (3.9)
Centrally acting α-blocker 117 (3.2)
Direct renin blocker 24 (0.7)
HDD according to medication class
β-Blocker 1.0 (0.8) [0.125-4]
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 1.2 (0.8) [0.125-6]
Calcium channel blocker 1.3 (0.6) [0.125-4]
Thiazide-like diuretic 0.9 (0.5) [0.072-2]
Potassium-sparing diuretic 0.6 (0.3) [0.25-2.75]
Other vasodilator 0.9 (0.6) [0.1-3]
Centrally acting α-blocker 0.6 (0.4) [0.125-1.5]
Direct renin blocker 1.3 (0.5) [1-2]
Abbreviations: HDD, hypertension daily dose; SBP,
systolic blood pressure.
a Total of 3625 visits for 319 patients.
b All HDD and medication counts are from clinical
note review.
c All patients had at least 3 medications on 2
consecutive visits over 2 years, but this did not
preclude some having individual visits while taking
fewer than 3 medications. Of 3625 visits, 50 visits
had 0 HDDs, thus resulting in the range of HDDs
including 0.


















Coefficient of correlation r = 0.92 (95% CI, 0.89-0.95);
P < .001; R2 = 0.85. Adjusted for clustering of visits
within patient.
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965 visits (28.8%) with 0.5 to 1.5 HDDs were associated with 3 or 4 medications. Using only the
number of medications, 1527 visits (42.1%) would overestimate intensity owing to 1 or more low-dose
medications (0.5 HDDs). Conversely, the number of medications belied the intensity in 425 visits
(11.7%) that include 1 or more medication at maximum beneficial dose or more (2 HDDs).
Discussion
We developed a method that standardizes doses across common BP medications based on
hypertension trial–proven maximum doses associated with cardiovascular benefit. This method uses
pharmacy fill data that are available in health system administrative data and can flexibly be applied
to any given day or visit. We validated this new measure—total HDDs, measured on days of primary
care visits—and found it to be highly correlated with the dose intensity documented in the clinical
notes on those same days.
Previous studies have proposed that measuring treatment intensity for older patients should
consider not only whether a BP target is achieved but also the number of medications an older
patient is receiving because an older adult with low BP taking 3 medications is being treated more
aggressively than an older adult with the same BP but taking no medications or 1 or 2
medications.13,32 With this additional dose information, we can gain an even more comprehensive
measure of hypertension treatment intensity with far more granularity than with dichotmous BP
targets or medication counts alone. In health care systems in which detailed pill counts and patient
interviews are not possible, this method may efficiently measure hypertension treatment intensity.
Given the many choices of BP medications demonstrated by trials to be associated with clinical
benefit, this method offers a continuous measure of treatment intensity that can holistically assess
the association between treatment, BP, and outcomes.
Table 3. Pharmacy HDD Discrimination for More Intensive vs Less Intensive Hypertension Treatment Regimens
Defined by Clinically Noted HDD
Definition of intensive treatment by clinically
noted HDDs and pharmacy HDDs Sensitivity, % Specificity, % C statistic (95% CI), %
≥2.0 HDDs 91.5 94.1 92.8 (92.0-93.7)
≥3.0 HDDs 85.7 95.5 90.6 (89.6-91.6)
≥4.0 HDDs 86.1 97.3 91.7 (90.5-92.9)
≥5.0 HDDs 83.3 98.7 91.0 (89.3-92.7)
≥6.0 HDDs 77.2 99.0 88.1 (85.5-90.6)
Abbreviation: HDD, hypertension daily dose.
Table 4. Association Between Categories of Pharmacy HDD and Number of BP Medication Classesa
HDD categories Visits
No. of BP medication classes
0 1 2 3 4 5 6 Mean (SD) [range]
≤0.5 308 67 165b 69b 7b 0 0 0 1.05 (0.73) [0-3]
>0.5 to ≤1.5 965 0 91 596b 250b 28b 0 0 2.22 (0.65) [1-4]
>1.5 to ≤2.5 759 0 61 367 290b 40b 1b 0 2.41 (0.72) [1-5]
>2.5 to ≤3.5 642 0 3c 187 394 56b 2b 0 2.79 (0.61) [1-5]
>3.5 to ≤4.5 441 0 1c 53c 251 113 23b 0 3.24 (0.73) [1-5]
>4.5 to ≤5.5 246 0 0 39c 77c 107 23 0 3.46 (0.87) [2-5]
>5.5 to ≤6.5 147 0 0 4c 46c 85c 10 2 3.73 (0.69) [2-6]
>6.5 117 0 0 0 13c 79c 25c 0 4.10 (0.56) [3-5]
Total 3625 67 321 1315 1328 508 84 2 2.59 (0.98) [0-6]
Abbreviations: BP, blood pressure; HDD, hypertension daily dose.
a Total of 3625 visits for 319 patients.
b Indicates visits (total 1527 [42.1%]) in which the number of BP medications
overestimates intensity owing to 1 or more medications at low dose.
c Indicates visits (total 425 [11.7%]) in which the number of BP medications
underestimates intensity owing to 1 or more medications at maximum beneficial dose
or more.
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In this study, we applied dose information at every primary care visit and validated this measure
on those days. This measure can flexibly be applied on any day, for example, at set intervals, such as
the last day or last visit of each quarter or year. In an observational study, one could apply the
measure at fixed time points after an index day (eg, enrollment into a health plan or after a fixed
interval after implementation of a quality improvement intervention).
This method may increase our understanding of prescribing patterns in terms of both HDDs and
medication counts in interventional studies. Clinical trials typically describe the intervention effect
in terms of medication counts only; adding dose intensity may further convey the intensity of
intervention necessary to gain the clinical benefits of the trial. Nonpharmacologic interventions, such
as diet and exercise, may also be associated with decreases in hypertension medication intensity as
a proximal outcome. For example, one study of improved sleep apnea treatment used reduction in
antihypertension medication–adjusted BP as an outcome, thus reflecting improvement in
hypertension severity if BP doses were decreased despite an equivalent BP.33 An intervention that
decreases medication use would be valuable from a health care use perspective and a patient
preference perspective. Moreover, because some adverse effects are dose dependent, a decrease in
dose would presumably also decrease risk of downstream adverse effects.10,34,35
Modern clinical trials have provided evidence of the benefit of treating hypertension using
optimized doses of older drugs, such as diuretics and β-blockers, and including newer medications,
such as calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor
blockers,15,17,36 thus allowing us to develop this new taxonomy for standardizing antihypertension
doses based on clinical benefit. Our taxonomy improves on the prior ATC/DDD system,16 which was
intended as a stable measure over time and did not provide “judgements about relative efficacy of
drugs and groups of drugs.”16 Our new HDD measure may facilitate future study of the trade-offs
between multiple low-dose regimens and fewer maximum-dose regimens, benchmarked to trial
evidence of cardiovascular benefit.
In this validation sample of older veterans treated for hypertension with multiple medications,
we found that a substantial proportion of visits included low doses of those medications. Because
guidelines recommend angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
for kidney protection for chronic kidney disease and/or diabetes, as well as for cardiovascular
prevention for diabetes and atherosclerotic cardiovascular disease,37-39 we would expect that
patients with multiple comorbidities would be taking multiple, but lower-dose, medications to gain
benefits for these comorbid conditions.
Furthermore, greater medication regimen complexity has been associated with poorer
adherence,40,41 but dose burden is understudied as a potential patient-centered factor in BP control.
Hypertension daily doses may also be used as a way to help gauge the complexity of patients’ BP
medication regimens (eg, as an outcome of a medication simplification intervention).
Despite the very high correlation of the pharmacy HDD with the clinically noted HDD, we found
that pharmacy HDDs were lower than clinically noted HDDs. The most likely reason was our method
of reducing estimated HDDs for late refills, therefore more closely matching what the patient took. If
the patient took fewer pills than recommended (ie, nonadherence), then we would observe a
mismatch between pharmacy HDD and clinically noted HDD. Although VA patients report better
adherence than non-VA patients owing to lower cost or no cost for filling medications,42 our finding
is congruent with what has been described for older patients with hypertension.43 Last, some of the
difference could have resulted from out-of-pocket payments (ie, low-cost generic programs) from
filling prescriptions at non-VA pharmacies.
Strengths and Limitations
This study has some strengths, including the use of 2 sources of pharmacy data (VA system and
Medicare Part D), an external source of validation (medical record review), and data from a national
health care system. Although there have been many changes to guidelines and BP targets in the last
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several years, our study preceded these changes (ie, the systolic BP target [<140 mm Hg] was
identical to the present).
This study also has several limitations. First, we were unable to validate doses for BP-lowering
medications with as-needed or frequent changes (eg, loop diuretics) or for medications infrequently
documented for hypertension treatment (eg, α-blockers for prostatic hypertrophy). Second, because
our study focused on older veterans, the sample included mostly men, thus potentially limiting
generalizability to women, although BP medication fill behavior is similar between the sexes.44 Third,
this was a cross-sectional validation of dose accuracy. Validation longitudinally for small changes in
dose over time, or linked externally to cardiovascular outcomes or adverse events, is beyond the
scope of this research. Fourth, as described previously,13 we studied a more intensely treated sample
of veterans than average, so it is possible that our results may not be generalizable to veterans with
less complex treatment regimens.
Conclusions
We have developed and validated an algorithm to identify the degree of hypertension treatment
intensity that is a more precise measure of intensity than number of BP medications or BP alone. Our
results may pave the way for further studies of dose intensity and health outcomes, including
programs to increase or decrease hypertension treatment intensity or to compare treatment
intensity between clinicians, clinics, and health care systems.
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